

Prescription Drug Advisory Boards: **Where They Are and Why They Matter to Patients**

[PART 2]

Why are Some “High-Cost” Therapies Targeted by PDABs

PDABs are increasingly targeting life-saving medications, including those for rare diseases and those related to public health initiatives, like Cancer and HIV medications and Hepatitis C cures. While well-intended, **the impacts of these actions threaten the patient-provider relationship** and the funding safety-net providers rely upon to provide **timely, appropriate life-saving care**.

Here's a look at how many patients might be negatively impacted by PDABs:

			Cancer	HIV	Hepatitis C Total
CO		Colorado	24,280	13,442	1,840
ME		Maine	9,151	1,693	840
MD		Maryland	30,603	33,467	2,202
MN		Minnesota	30,505	9,223	908
NH		New Hampshire	8,177	1,365	50
NJ		New Jersey	50,346	35,207	2,461
OH		Ohio	65,151	24,084	6,829
OR		Oregon	20,141	7,484	1,678
WA		Washington	36,017	14,591	2,678

Sources:

[CDC Cancer Link](#) | [CDC HIV Link](#) | [CDC HCV - Chronic](#) | [CDC HCV - Perinatal](#) | [CDC HCV - Acute](#)